Unidad de cáncer digestivo

Unidad de cáncer digestivo

 

 

  • A Randomized, multicenter, double blind, phase III study of adjuvant Nivolumab or Placebo in patients with resected esophageal, or gastroesophageal junction cáncer. Investigador Principal Antonio Cubillo

 

  • Seguridad y eficacia del ramucirumab en pacientes con cáncer de estómago avanzado en la Unión Europea y Norteamérica: Registro de observación prospectivo (I4T-MC-JVDD). Investigador Principal Antonio Cubillo

 

  • A Phase 3, Double-blind, Randomized Study of BGB-290 versus Placebo as Maintenance Therapy in Patients with Inoperable Locally Advanced or Metastatic Gastric Cancer that Responded to Platinum-based First-line Chemotherapy Investigador Principal Antonio Cubillo

 

 

  • A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA) /Irinotecan (FOLFIRI)/Cetuximab with a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients with BRAF V600E-mutant Metastatic Colorectal Cancer Investigador Principal Enrique Sanz

 

 

  • ENSAYO DE FASE II PARA EVALUAR LA EFICACIA Y SEGURIDAD DE FOLFIRI + PANITUMUMAB COMO TRATAMIENTO DE PRIMERA LÍNEA EN PACIENTES ANCIANOS CON CÁNCER COLORRECTAL METASTÁSICO NO RESECABLE, RAS/BRAF NO MUTADO Y BUEN ESTADO FUNCIONAL. Investigador Principal Antonio Cubillo

     
  • Phase I dose-escalation of S 95005 (TAS-102) in combination with oxaliplatin in metastatic colorectal cáncer. Investigador Principal Antonio Cubillo

     
  • ABT-165 plus FOLFIRI vs Bevacizumab plus FOLFIRI in Metastasic Colorectal Cancer Previously treated with Fluopyrimidine/Oxaliplatino  and Bevaxizumab Investigador Principal Antonio Cubillo

 

 

  • Estudio fase I con escalada de dosis de virus oncolítico VCN-01 administrado intravenosamente con o sin gemcitabina y Abraxane® en tumores sólidos. Investigador Principal Rafael Alvarez.

     

     
  • A PHASE II STUDY OF DURVALUMAB (MEDI4736) PLUS TREMELIMUMAB FOR THE TREATMENT OF PATIENTS WITH ADVANCED NEUROENDOCRINE NEOPLASMS OF GASTROENTEROP ANCREATIC OR LUNG ORIGIN (THE DUNE TRIAL) Investigador Principal Antonio Cubillo

     
  • A PHASE III, OPEN LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB IN COMBINATION WITH BEVACIZUMAB COMPARED WITH SORAFENIB IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METATSASIC HEPATOCELULLAR CARCINOMA Investigador Principal Antonio Cubillo

     
  • Phase 2, Open-label, Multicenter Study to Investigate the Efficacy, Safety, and Pharmacokinetics of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Patients with Previously Treated Hepatocellular Unresectable Carcinoma Investigador Principal Antonio Cubillo

     
  • HEPANOVA: A Phase II Trial of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Sorafenib For Advanced Hepatocellular Carcinoma (HCC) Investigador Principal Antonio Cubillo

     
  • Estudio fase II, multicéntrico, con un único brazo de tratamiento, de BGJ398 oral en pacientes adultos con colangiocarcinoma avanzado o metastásico, con fusiones del gen FGFR2 u otras alteraciones genéticas del FGFR que han progresado o que son intolerantes a quimioterapia basada en platino. Investigador Principal Rafael Alvarez

     
  • ENSAYO DE FASE III, MULTICÉNTRICO, RANDOMIZADO, DOBLE CIEGO CONTROLADO CON PLACEBO TRATADO CON AG-120 PREVIAMENTE TRATADOS CON COLANGIOCARCINOMA NO RESECABLE O METASTÁSICOS Y MUTACION IDH. Investigador Principal Antonio Cubillo

     
  • A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF VARLITINIB PLUS CAPECITABINE VERSUS PLACEBO PLUS CAPECITABINE IN PATIENTS WITH ADVANCED OR METASTATIC BILIARY TRACT CANCER AS SECOND-LINE SYSTEMIC THERAPY Investigador Principal Antonio Cubillo

     
  • ESTUDIO OBSERVACIONAL DE BIOPSIA LÍQUIDA EN PACIENTES CON ADENOCARCINOMA DE PÁNCREAS POTENCIALMENTE QUIRÚRGICO PARA CARACTERIZAR MUTACIONES DE KRAS COMO MARCADOR PRONÓSTICO. Investigador Principal Enrique Sanz

 

  • A RANDOMIZED, PHASE 3, STUDY OF AM0010 in combination with FOLFOX compared with FOLFOX alone as second-line Therapy in patient with metastaisc pancreatic cancer that has progressed during or following a first-line gemcitabine containing regimen. Investigador Principal Antonio Cubillo

 

  • A Randomized, Phase 3 Study of Eryaspase in Combination with Chemotherapy versus Chemotherapy Alone as Second-Line Treatment in Patients with Pancreatic Adenocarcinoma. Investigador Principal Antonio Cubillo

     
  • PHASE 3, Study of  BBI-608 plus nab-Paclitaxel with Gemcitabine in Adult patient s with Metastasic Pancreatic Adenocarcinoma Investigador Principal Rafael Alvarez

     
  • A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan (nal-IRI)-containing Regimens versus nab-paclitaxel plus Gemcitabine in Patients with Previously Untreated, Metastatic Pancreatic Adenocarcinoma. Investigador Principal Antonio Cubillo
  •  

 

 


To Top